Cervical Cancer Screening with HR-HPV Testing and Self-sampling
This study aims to improve cervical cancer screening in underserved communities by looking at a new approach called primary HR-HPV testing with self-sampling. HR-HPV testing checks for the human papillomavirus (HPV) that can cause cervical cancer. The study wants to understand how healthcare providers, staff, and patients feel about using self-sampling for these tests. The goal is to increase the number of people getting screened for cervical cancer and to make sure those with abnormal results get the follow-up care they need. You may be able to join if you are a woman between 18 and 65 years old and are eligible for cervical cancer screening. The study hopes to increase screening rates by 10% and improve awareness of this new testing method.
- Study design
- This is an interventional study with a planned enrollment of 7100 participants. It involves different groups, including patients, healthcare providers, and community members.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be monitored through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Safety and Adverse Events (AEs). Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03Through study completion; an average of 1 year.